Thursday, September 24, 2015

News: Conventus Orthopaedics' Quest to Deliver Cage Technology Solution for Fractures Includes New Proximal Radius Product Indication for Innovative 3-Dimensional Fixation

Conventus Orthopaedics, Inc.
MINNEAPOLIS, MN--(Marketwired - September 23, 2015) - Conventus Orthopaedics Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new Conventus Cage™ PR (Promixal Radius) System, designed as an innovative solution to address fractures of the radial head and neck. This new implant, a third approved indication for the company, continues Conventus' momentum in providing solutions for fracture fixation throughout the body based on a self-expanding scaffold.

Utilizing the shape memory properties of nitinol, the Conventus Cage™ expands within the bone creating robust, stable fixation and thus prevents collapse of the fracture repair. Similar to the company's first two products, the Conventus Cage™ DR and Conventus Cage™ PH, the new Conventus Cage™ PR creates a rigid substrate designed to self-expand within the bone to avoid interference with soft tissues and ultimately improve upon pronation and supination. Its self-expanding scaffold provides options to achieve reliable repairs with fewer compromises in peri-articular fractures. The implant is designed to address important limitations of conventional approaches to radial head and neck repairs while allowing for preservation of the bony anatomy and preserving future treatment options.
Paul Buckman, Conventus President and CEO, said, "The approval of this additional indication reflects our commitment to provide more innovative solutions and options for surgeons working to repair orthopedic fractures throughout the body. Our overall goal is to provide a complete platform technology enabling surgeons to treat all trauma and fracture repairs from a 3-dimensional approach."
Conventus designed and developed the proprietary device in close consultation with an expert group of surgeon advisors. The design is aligned with the principles of the Conventus 3-dimensional Cage platform technology, which emphasize preservation of tissues and blood supply at the fracture site, creating a strong foundation by stabilizing bone fragments and facilitating early motion through less invasive procedures.
The Conventus Cage™ PR is indicated for treatment of proximal radial fractures when internal fixation is desired, and fracture fragments are not too numerous and/or too small to be stabilized with the use of the device. For more information regarding use of the device please refer
About Conventus Orthopaedics, Inc.
Conventus Orthopaedics, Inc. was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a platform technology with less invasive solutions to a broad range of challenging peri-articular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions for fractures in and around the joints. The company is dedicated to working with surgeons to improve healing and enable their patients' return to normal activities.


No comments:

Post a Comment